


WHAT'S HAPPENING at GRS

Newsletter #17 - March, 2022

Visit: <http://www.ghresearchsociety.org>



UPCOMING MEETINGS

Conference: The Growth Hormone/Prolactin Family in Biology & Disease in Athens, Ohio

This Federation of American Societies for Experimental Biology (FASEB) conference will take place in Athens, OH from May 15-19,

2022. The meeting will feature novel, translational research advances in GH/PRL biology with a goal of fostering new national and international collaborations and supporting emerging investigators/trainees. A celebration to honor Dr. John Kopchick will occur the first evening of the meeting. For more information visit: <https://www.faseb.org/meetings-and-events/src-events/growth-2022>

Congress: 24th European Congress of Endocrinology (ECE) 2022 in Milan, Italy

The European Society of Endocrinology is excited to announce that the 24th ECE will take place from May 21-24, 2022. Join colleagues in person in Milan, where you will connect with world renowned speakers and leading-edge science. For the first time ever, the congress features a unique registration option ECE @Home, offering you access to the Congress from the comfort of your own home or office if you are unable to travel to Milan.

GRS-ESE workshop at the 24th ECE, May 22nd Milan, Italy

Safety of growth hormone treatment in survivors of cancer and intra-cranial tumors – A Growth Hormone Research Society Consensus statement

Chairs: *Sally Radovick* (president GRS) and *Andrew R. Hoffman* (past president GRS)

10:10h **Safety of GH replacement in childhood cancer survivor** - *Hanneke van Santen*, Netherlands

10:40h **Safety of GH replacement in adults survivors of cancer and intracranial tumors** - *Niki Karavitaki*, United Kingdom

11:10h **Long-acting GH in the context of cancer survivors. The pediatric and adult perspective** - *Kevin C.J. Yuen*, USA and *Peter Clayton*, UK

It's been a long time since our last newsletter (Feb 2020)! We at GRS hope that this communication finds you, your families & friends well. It's been a long, anguish filled, impactful 'journey' through the Covid ordeal. Let's hope that soon we will be able to put it behind us!

At this time, it's good to recall GRS' mission: To promote scientific and clinical advancement in the fields of growth hormone and insulin-like growth factors.


We at GRS are proactively adapting to the new 'normal' and are re-defining our methods to meet our goals. As such and as you know, the much-anticipated GRS-IGF International Congress to be held in Brazil was canceled. We are not sure if, when, or where the next Congress venue will be, but, the GRS council is 'on top of this' and will alert everyone once plans have been firmly established. At the current time, GRS is organizing a 'mini' event at the upcoming ESE meeting in Milan, Italy. The program is in the UPCOMING MEETINGS section of this newsletter. We hope to see you there!

Thus, although this newsletter is somewhat tardy, GRS has come out of its hibernation and will keep you posted as to "What's Happening at GRS".

WHAT'S HAPPENING at GRS

Newsletter #17 - March, 2022

Visit: <http://www.ghresearchsociety.org>



16th GRS Workshop – Outcome

The recent virtual workshop on “Safety of GH treatment in cancer survivors” successfully held in 2021 with over 50 participants. A review paper concerning this meeting was published prior to the meeting (Pituitary. 2021 Oct;24(5):810-827). The outcome of the workshop resulted in a manuscript that has been submitted and is under review.

16th GRS Workshop – A new Platform

The GH Research Society held its 16th Workshop on the topic of Safety of GH Treatment in Cancer and Intracranial Tumor Survivors in Children and Adults.

This invitation-only workshop was performed through a web-based platform. We had adapted the schedule of this web-based structure with short online meetings taking place on three different occasions last year (June 9th and 16th, and September 29th). The workshop was organized with the support of the European Society of Endocrinology. Other major endocrine societies had also been invited to nominate delegates to the workshop.

Additionally, representatives from the regulatory agencies, EMA and FDA, attended. A review paper on the topic had been written by members of the program organizing committee, and it was distributed to the delegates prior to the start of the meeting. The format of each workshop had been modified over the years, but the backbone of plenary lectures set the scene followed by breakout group discussions of more specific themes or questions.

The final session was devoted to drafting a statement summarizing the outcome of the workshop that was submitted for publication. GRS had published the results of its previous 15 workshops that had ‘stood’ the test of time.

Potential Up-Coming Workshop Topics:


Update on diagnosis of GHD
Genetics of short stature
Transition of GHD patients

SUGGESTIONS ARE WELCOME!

WHAT'S HAPPENING at GRS

Newsletter #17 - March, 2022

Visit: <http://www.ghresearchsociety.org>



Aeterna Zentaris

ascendis
pharma

BiOMARIN

CHIASMA

Consilient
Health

Crinetics
Pharmaceuticals

FERRING
PHARMACEUTICALS

GenSci
金赛药业

ids
ImmunoDiagnostics

IPSEN
Innovation for patient care

lumos
PHARMA

MERCK

novo nordisk

Pfizer

SANDOZ
Biopharmaceuticals

STRONGBRIDGE
BIOPHARMA

GRS COUNCIL:

GRS welcomes Dr. Sally Radovick as our new President and wishes her well. We also thank our past president, Dr. Andrew Hoffman, for his excellent dedication and work during these convoluted 'Covid' times. GRS is in the process of organizing an online voting system for Council Seats. More information will follow as to how the system will work.

CURRENT GRS COUNCIL:

President: Sally Radovick

Past President: Andy Hoffman

Secretary: Martin Bidlingmaier

Treasurer: Jens Otto L. Jorgensen

Members: Margaret Boguszewski, Adda Grimberg, Catherine

Choong, Peter Kamenicky, Xiaoping Luo

Communications: John Kopchick

New membership programs: Catherine Choong

Liaison to ESE: Gudmundur Johansson

SUPPORTING MEMBERS

GRS sincerely thanks its supporting members. During the Covid Pandemic, we have not interacted with you as we have in the past. In order to re-initiate our interactions, we plan to convene future meetings (virtual or in person) for discussion of strategies to continue our mission of advancement of GH and IGF basic and clinical research. Your past suggestions are very important and do help guide us especially related to our Workshops and meeting agendas. **We would like to welcome Consilient Health as our newest supporting member.**

**GRS is grateful to the following companies
who have supported GRS in recent years:**

Aeterna Zentaris

BioMarin

Consilient Health

Ferring Pharmaceuticals

Immunodiagnostic Systems

Lumos Pharma

Novo Nordisk

Sandoz Biopharmaceuticals

Ascendis Pharma

Chiasma Inc

Crinetics Pharmaceuticals

GeneScience Pharmaceutical

IPSEN Innovation for patient care

Merck KGaA


Pfizer

Strongbridge Biopharma

WHAT'S HAPPENING at GRS

Newsletter #17 - March, 2022

Visit: <http://www.ghresearchsociety.org>




Most recently and as reported above, a successful workshop was held on 'Safety of GH Treatment in Cancer and Intracranial Tumor Survivors in Children and Adults.' Although this program required a virtual format, it has resulted in the submission of a manuscript. We hope you will join many of us at the FASEB Science Research Conference (SRC) 'The Growth Hormone (GH)/ Prolactin (PRL) Family in Biology & Disease Conference' in Athens, Ohio, and the 24th European Congress of Endocrinology (ECE) 2022 in Milan, Italy. We are planning a GRS-sponsored mini-symposia and an opportunity for networking with colleagues. I want to thank our supporting members for their sustained generosity. We certainly would not be able to provide these programs to you without them.

I want to begin plans for new initiatives of the GRS, for which I ask for your help. In the coming months, we will roll out avenues that will allow the GRS to strengthen and reinvigorate our existing programs and launch new initiatives to help you engage with us and our communities. Please consider what topics you would like as future 'Workshops' and send me your suggestions. We wish to select topics relevant to your research interest and are of most benefit to those we serve—my email: s.radovick@rutgers.edu. We want to hear your ideas and invite you to participate in shaping GRS's future and become even more active members of this organization.

I look forward to working and connecting with you.
With gratitude,
Sally

PITUITARY SOCIETY NEWS

GRS and the Pituitary have formed a strong relationship and during Covid we continued to communicate, maintain, and enhance our friendship. Related to this is the proud accomplishment of having the Journal, Pituitary, as the official journal of the Pituitary Society and GRS. We are very happy, proud, and honored by this relationship and look forward to future successful collaborative events.



A MESSAGE FROM OUR PRESIDENT

As we begin the New Year, I sincerely hope that 2022 will allow all of us to live more 'normal' lives. I want to thank Andy Hoffman for his leadership as President during these most difficult times. In my first Presidential letter, I am humbled and excited by the privilege to serve as the President of this dynamic and prestigious organization. I am enthusiastic about working with my fellow officers. I continually am in awe at their commitment and dedication. We now strive to return to a modified normal and attainment of our continuing goals. Andy, I, and the other members of the Council have continued to promote the goals of GRS.